| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 技术授权许可(元) | 2,900,445.70 | 6,622,425.52 | 3,875,496.93 | 43,820,223.87 | 14,374,075.42 |
| 销售商品(元) | 292,529,501.33 | - | 235,582,043.18 | - | 200,117,058.18 |
| 西达本胺片销售(元) | - | 466,605,983.75 | - | 466,792,080.22 | - |
| 西格列他钠销售收入(元) | - | 42,247,926.67 | - | 15,821,028.79 | - |
| 其他(元) | 6,730,562.02 | 2,097,311.10 | - | - | - |
| 营业成本(元) | |||||
| 技术授权许可(元) | - | - | - | - | - |
| 销售商品(元) | 33,253,547.67 | - | - | - | - |
| 西达本胺片销售(元) | - | 18,245,099.91 | - | 14,831,828.86 | - |
| 西格列他钠销售收入(元) | - | 35,725,607.44 | - | 14,143,637.96 | - |
| 其他(元) | 3,262,796.80 | 991,292.61 | - | - | - |
| 毛利(元) | |||||
| 技术授权许可(元) | 2,900,445.70 | 6,622,425.52 | - | 43,820,223.87 | - |
| 销售商品(元) | 259,275,953.66 | - | - | - | - |
| 西达本胺片销售(元) | - | 448,360,883.84 | - | 451,960,251.36 | - |
| 西格列他钠销售收入(元) | - | 6,522,319.23 | - | 1,677,390.83 | - |
| 其他(元) | 3,467,765.22 | 1,106,018.49 | - | - | - |
| 毛利率(%) | |||||
| 技术授权许可(%) | - | - | - | - | - |
| 销售商品(%) | 88.63 | - | - | - | - |
| 西达本胺片销售(%) | - | 96.09 | - | 96.82 | - |
| 西格列他钠销售收入(%) | - | 15.44 | - | 10.60 | - |
| 其他(%) | 51.52 | 52.74 | - | - | - |
| 收入构成(%) | |||||
| 技术授权许可(%) | 0.96 | 1.28 | 1.62 | 8.32 | 6.70 |
| 销售商品(%) | 96.81 | - | 98.38 | - | 93.30 |
| 西达本胺片销售(%) | - | 90.15 | - | 88.67 | - |
| 西格列他钠销售收入(%) | - | 8.16 | - | 3.01 | - |
| 其他(%) | 2.23 | 0.41 | - | - | - |
| 毛利构成(%) | |||||
| 技术授权许可(%) | 1.09 | 1.43 | - | 8.81 | - |
| 销售商品(%) | 97.60 | - | - | - | - |
| 西达本胺片销售(%) | - | 96.92 | - | 90.85 | - |
| 西格列他钠销售收入(%) | - | 1.41 | - | 0.34 | - |
| 其他(%) | 1.31 | 0.24 | - | - | - |